<SEC-DOCUMENT>0001144204-18-053084.txt : 20181010
<SEC-HEADER>0001144204-18-053084.hdr.sgml : 20181010
<ACCEPTANCE-DATETIME>20181010060329
ACCESSION NUMBER:		0001144204-18-053084
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20181010
FILED AS OF DATE:		20181010
DATE AS OF CHANGE:		20181010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SINOVAC BIOTECH LTD
		CENTRAL INDEX KEY:			0001084201
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			B9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32371
		FILM NUMBER:		181114820

	BUSINESS ADDRESS:	
		STREET 1:		NO. 15 ZHI TONG ROAD,
		STREET 2:		ZHONGGUANCUN TECH PARK, CHANGPING DISTR.
		CITY:			BEIJING
		STATE:			F4
		ZIP:			102200
		BUSINESS PHONE:		86-10-82890088

	MAIL ADDRESS:	
		STREET 1:		NO. 15 ZHI TONG ROAD,
		STREET 2:		ZHONGGUANCUN TECH PARK, CHANGPING DISTR.
		CITY:			BEIJING
		STATE:			F4
		ZIP:			102200

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NET FORCE SYSTEMS INC
		DATE OF NAME CHANGE:	19991110
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tv504580_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of October 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">--------------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-32371</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">----------</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt">SINOVAC BIOTECH
LTD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No. 15 Zhi Tong Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Zhongguancun Science and Technology Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Changping District</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Beijing 102200, People&rsquo;s Republic
of China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F  <FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&#9;</FONT> <FONT STYLE="font-family: Wingdings">&uml; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1):________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7):________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">SINOVAC BIOTECH LTD.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">/s/ Nan Wang</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Nan Wang</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: October 10, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"><FONT STYLE="font-weight: normal; font-variant: normal">Exhibit
99.1&#9;Press Release</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal; font-variant: normal"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal; font-variant: normal">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv504580_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Sinovac
Comments on Unauthorized Use of Falsified Sinovac Hong Kong&rsquo;s Company Seal and Subsidiary Board Member Signatures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 09, 2018 11:51 PM Eastern Daylight Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA)
(&quot;Sinovac&quot; or the &quot;Company&quot;), became aware Monday October 8, 2018 that unauthorized changes have been made
to the Hong Kong Companies Registry for Sinovac Biotech (Hong Kong) Limited (&ldquo;Sinovac HK&rdquo;) and that unauthorized changes
have been made to the Industry and Commerce Bureau of Beijing for Sinovac Biotech Co., Ltd. (&ldquo;Sinovac Beijing&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unknown individuals have used a falsified version of the company
seal of Sinovac HK and used unauthorized forgeries of the signatures of Mr. Weidong Yin and Ms. Nan Wang, Directors of Sinovac
HK, to submit false letters of resignation to the Hong Kong Companies Registry in an attempt to remove Mr. Weidong Yin and Ms.
Nan Wang from the Board and replace them with nominees of the Sinobioway Consortium, led by Sinobioway Biomedicine Co., Ltd. (&quot;Sinobioway&quot;),
a minority shareholder of Sinovac Beijing, and a group of Sinovac&rsquo;s shareholders led by 1Globe and OrbiMed (collectively,
the &ldquo;Dissident Shareholders&rdquo;) who have repeatedly attempted to take control of Sinovac Biotech Co. and its subsidiaries
and affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, without authorization on August 28, 2018, Aihua
Pan, a member of the Board of Sinovac Beijing, who was appointed by Sinobioway, held a purported Sinovac Beijing Board meeting.
At the meeting, Aihua Pan attempted to seize control of Sinovac Beijing by dismissing Mr. Weidong Yin, Ms. Nan Wang and Mr. Dawei
Mao from the Board and replacing them with nominees of Sinobioway and the Dissident Shareholders. Aihua Pan also attempted to dismiss
Mr. Yin from the General Manager position and appoint himself as General Manager. In addition, the meeting purported to amend the
company charter to change the authorized representative of Sinovac HK from Mr. Yin to Jianzeng Cao, a representative of Sinobioway
and the Dissident Shareholders. The Board resolutions of the purported meeting contain an unauthorized forgery of Director Yuk
Lam Lo&rsquo;s signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As confirmed by Zhongtian Forensic Examination Center, which
issued an Examination Opinion, &ldquo;Zhongtian Forensic 2018 Wenjianzi No. 263&rdquo;, dating back to April, 2018, Aihua Pan and
Sinobioway have been using Sinovac HK&rsquo;s forged company seal and an unauthorized forged signature of Mr. Weidong Yin to falsely
claim that Sinovac Beijing&rsquo;s business license, company seal, contract special seal, legal person seal, and finance seal had
been lost and are therefore invalid. Sinovac HK has reported these fraudulent actions to the public security of Haidian District,
City of Beijing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Weidong Yin and Ms. Nan Wang remain appointed and authorized
directors of Sinovac HK; Mr. Weidong Yin, Ms. Nan Wang and Mr. Dawei Mao remain appointed and authorized directors of Sinovac Beijing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors and management of publicly traded Sinovac
Biotech Ltd., which remain unchanged by the actions of Sinobioway and the Dissident Shareholders, are closely monitoring these
unauthorized actions purportedly taken at Sinovac HK and Sinovac Beijing and continue to execute their fiduciary duties to act
in the best interests of the Company and all shareholders as the Company moves forward in its mission to develop vaccines that
enhance health in China and around the world and create shareholder value. Furthermore, the Board of Directors and management of
Sinovac are vigorously defending the rights of all shareholders in all applicable courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The current members of the board of directors of Sinovac Biotech
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mr. Weidong Yin</I>&nbsp;has served as our chairman, president,
chief executive officer and secretary since September 2003. He previously worked as a medical doctor in infectious disease at the
China Center for Disease Control and Prevention, Tangshan City, Hebei province. Mr. Yin has been dedicated to hepatitis research
for over 20 years and was instrumental in the development of Healive. In addition, Mr. Yin has been appointed as the principal
investigator by the Chinese Ministry of Science and Technology for many key governmental R&amp;D programs such as Inactivated Hepatitis
A Vaccine R&amp;D, Inactivated SARS Vaccine R&amp;D and New Human Influenza Vaccine (H5N1) R&amp;D. He is also the president of
Zhongguancun Listed Companies Association. He obtained his MBA from the National University of Singapore.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mr. Simon Anderson</I>&nbsp;has served as an independent
director of our company since July 2004. He is a member of our audit, compensation, and corporate governance and nominating committees.
Mr. Anderson&rsquo;s professional experience is as a Chartered Professional Accountant of British Columbia with over 30 years&rsquo;
experience working as an executive officer and director of companies, including public companies listed on a number of North American
Stock exchanges. His experience includes nearly a decade of service as the Chief Financial Officer of IBC Advanced Alloys Corp.,
a leading advanced alloys company, where he continues to serve as a director. Mr. Anderson previously served for over five years
as a director of WEX Pharmaceuticals Inc. while it was a publicly listed biopharmaceutical company dedicated to the development
and manufacture of innovative drug products. Prior to these positions he spent eight years at MCSI Consulting Services, Inc., a
company that provides consulting expertise in the areas of regulatory compliance, exchange listings, securities valuation and financial
operations and nine years in business valuation with BDO Canada LLP, a member of the world&rsquo;s fifth largest accounting network.
In these roles and others, he has developed extensive experience in financing, mergers and acquisitions, corporate governance and
securities regulation practices. Mr. Anderson received his Bachelor of Commerce in Accounting and Management Information Systems
from the University of British Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mr. Yuk Lam Lo</I>&nbsp;has served as an independent director
of our company since March 2006. Mr. Lo is a member of the audit, compensation and corporate governance and nominating committees.
Currently Mr. Lo is serving as the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau HKSAR, an Executive
Committee Member of the Chinese Manufacturers&rsquo; Association of Hong Kong (CMA) and Chairman of the Education Committee of
CMA. Mr. Lo is also the Honorary Founding Chairman of Hong Kong Bio-Organization. In the educational area, Mr. Lo has been elected
an Honorary Fellow of the Hong Kong University of Science and Technology. He is an Honorary Chairman of Hong Kong Food Safety Association,
Adjunct Professor of the Chinese University of Hong Kong and Honorary Professor of several universities in China. Mr. Lo was heavily
involved in several committees of the HKSAR Government. He had been appointed as Director of the Hong Kong Applied R&amp;D Fund
Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry &amp; Technology Development Council, and Chairman
of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, HKSAR. In China, Mr. Lo is a Member of Chinese
People&rsquo;s Political Consultative Conference in Jilin province, and a Consultant of the Centre for Disease Control and Prevention
of China. In the business sector, he is an Independent Director of Luye Pharma Group Limited (2186.HK) and CSPC Pharmaceutical
Group Limited (1093.HK).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mr. Kenneth Lee</I>&nbsp;is an independent director of Sinovac.
He has served on our board of directors since May 2011. In July 2012, the board appointed him as a member of the compensation committee
and corporate governance and nominating committee. Mr. Lee is a partner at SAIF Partners. SAIF Partners IV L.P. is currently the
largest shareholder of Sinovac. Mr. Lee has more than 20 years of experience across private equity investments, corporate finance,
and business development in China. He is a non-executive director on the boards of three Chinese portfolio companies publicly listed
on the stock exchanges in the United States and Hong Kong and a board director for four other private Chinese companies backed
by SAIF Partners. Mr. Lee is a graduate of Amherst College.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mr. Meng Mei&nbsp;</I>has served as an independent director
of our company since March 2012. Mr. Mei is the chairman of compensation committee, and member of the audit and corporate governance
and nominating committees. Mr. Mei founded TusPark, a science park established by Tsinghua University in 1994, to incubate high
growth companies. He has been the director of TusPark&rsquo;s development center since its inception. Mr. Mei is also the Chairman
of TusHoldings Co., Ltd., which is engaged in the development, construction, and management of TusPark and is providing services
to enterprises based in TusPark. TusHoldings Co., Ltd. is also involved in venture capital investments in China. Mr. Mei sits on
the judging expert panel of China&rsquo;s National Science &amp; Technology Award. He has developed courses on entrepreneurship
and new venture formation as a Tsinghua University professor and an entrepreneur. Mr. Mei holds a bachelor&rsquo;s degree in automation
from Tsinghua University, PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mr. Shan Fu</I>, Managing Partner at Vivo Capital since 2013,
joined Sinovac&rsquo;s Board of Directors. Prior to joining Vivo, Mr. Fu was Senior Managing Director in the Private Equity group
and the Chief Representative of Blackstone&rsquo;s Beijing Office. Additionally, Mr. Fu&rsquo;s qualifications include experience
in the Department of Foreign Investment in China&rsquo;s National Development and Reform Commission, the State Economic and Trade
Commission, the Office of Economic and Trade in State Council, and the Office of Production in State Council.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Sinovac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sinovac Biotech Ltd. is a China-based biopharmaceutical Company
that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza,
H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps. Healive, the hepatitis A vaccine manufactured by the
Company has passed the assessment under WHO Prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed
by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first
company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination
campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government
stockpiling program. The Company is developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China,
while also exploring growth opportunities in international markets. The Company has exported select vaccines to over 10 countries
in Asia and South America. For more information please refer to the Company&rsquo;s website at <U>www.sinovacbio.com</U>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Safe Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This announcement may include certain statements that are not
descriptions of historical facts, but are forward-looking statements. These statements are made under the &quot;safe harbor&quot;
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by
terminology such as &quot;will,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;future,&quot; &quot;intends,&quot; &quot;plans,&quot;
 &quot;believes,&quot; &quot;estimates&quot; and similar statements. Forward-looking statements involve risks, uncertainties and
other factors that could cause actual results to differ materially from those contained in any such statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contacts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor:</B><BR>
Sinovac Biotech Ltd.<BR>
Helen Yang<BR>
Tel: +86-10-8279-9871<BR>
Fax: +86-10-6296-6910<BR>
Email: <U>ir@sinovac.com</U><BR>
or<BR>
ICR<BR>
Bill Zima<BR>
Tel: +1-646-308-1707<BR>
Email: <U>william.zima@icrinc.com</U><BR>
or<BR>
<B>Media:</B><BR>
Abernathy MacGregor<BR>
Sheila Ennis<BR>
Tel: +1-415-745-3294<BR>
Email: <U>sbe@abmac.com</U><BR>
or<BR>
<B>China Media:</B><BR>
ICR<BR>
Edmond Lococo<BR>
Tel: +86-10-6583-7510<BR>
Email: <U>Edmond.Lococo@icrinc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
